Implications of COVID-19 on statistical design and analyses of clinical studies

This whitepaper discusses the major statistical principles that need to be considered when assessing the impact on trials due to the disruptions caused by COVID-19 including the role of Data Monitoring Committees (DMCs) and interim analyses for risk assessments and how to handle missing or delayed assessments in analyses and reports.